Literature DB >> 21326679

Heparin in interventional radiology: a therapy in evolution.

Stuart B Resnick1, Stephanie H Resnick, Joshua L Weintraub, Nishita Kothary.   

Abstract

Interventional radiology techniques made possible by the antithrombotic properties of heparin have revolutionized treatment for a myriad of disorders. Newer low-molecular-weight heparins (LMWHs) offer several advantages over unfractionated heparin (UFH), especially in chronic settings. They are increasing in popularity for use during vascular procedures. However, LMWH shares limitations with UFH such as heterogeneity, nonspecificity, and induction of thrombocytopenia. These drawbacks have led to a search for the next generation of antithrombotic agents. Homogeneous drugs targeting specific coagulation cascade molecules are now available. The number of alternative anticoagulant drug combinations presents clinicians with a confusing array of choices. The strengths and weaknesses of UFH, LMWH, and direct antithrombin agents are presented. The promising future of LMWH and hirudins is discussed.

Entities:  

Keywords:  Heparin; anticoagulation; bivalirudin; hirudin; interventional radiology; low-molecular-weight heparin

Year:  2005        PMID: 21326679      PMCID: PMC3036272          DOI: 10.1055/s-2005-871864

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  119 in total

1.  The elimination from plasma of intravenous heparin. An experimental study on dogs and humans.

Authors:  P OLSSON; H LAGERGREN; S EK
Journal:  Acta Med Scand       Date:  1963-05

Review 2.  Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis.

Authors:  M Talbot
Journal:  Semin Thromb Hemost       Date:  1989-07       Impact factor: 4.180

3.  Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.

Authors:  S S Rebello; C J Kasiewski; R G Bentley; S R Morgan; V Chu; J S Bostwick; S I Klein; M H Perrone; R J Leadley
Journal:  Thromb Res       Date:  2001-05-01       Impact factor: 3.944

Review 4.  Therapeutic rationale for antithrombin III in sepsis.

Authors:  S M Opal
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

5.  Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

Authors:  X Song; G Huhle; L Wang; U Hoffmann; J Harenberg
Journal:  Circulation       Date:  1999-10-05       Impact factor: 29.690

6.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.

Authors:  J A Bittl; J Strony; J A Brinker; W H Ahmed; C R Meckel; B R Chaitman; J Maraganore; E Deutsch; B Adelman
Journal:  N Engl J Med       Date:  1995-09-21       Impact factor: 91.245

7.  The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.

Authors:  R A Raschke; B M Reilly; J R Guidry; J R Fontana; S Srinivas
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

8.  Heparin kinetics determined by three assay methods.

Authors:  T D Bjornsson; K M Wolfram; B B Kitchell
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

9.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

Authors:  E M Antman
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

10.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.

Authors:  M Heras; J H Chesebro; W J Penny; K R Bailey; L Badimon; V Fuster
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

View more
  1 in total

Review 1.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.